Outsiders Have Form to Get Across the Line

Source: Herald Sun; Published: 5th November 2014

Now that the Melbourne Cup has been run and won, it is time to look at some companies with long odds that still might come rocketing down the home straight.

They might not have names that many sharemarket followers will recognise but they are at least in the race and small enough to achieve fast growth.

Our first tiddler, Virax Holdings, is likely to end the race with a different name altogether after it bought two clinical-stage cancer drugs that have nothing to do with

This is a company in rapid transition given that shareholders meet later this month to approve the deal, but with former Arana Theraputics executive Dr Robert Crombie in charge and experienced biotechnology player Paul Hopper on the board, there should be plenty of action within a short time.

To read the full article please download the document below.